Tin tức & Cập nhật

The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.

Extracellular vesicles enriched with the polymeric immunoglobulin receptor molecule contributes to tumorigenesis and cancer stemness in patients with hepatocellular carcinoma (HCC), reports a recent study.

A prospective clinical study conducted by the Hong Kong Baptist Hospital in collaboration with the Hong Kong Polytechnic University has demonstrated the feasibility of implementing respiratory-gated PET-CT for liver malignancies with improved image quality compared with ungated scans.

Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.

Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.

The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.